Purpose of Review <p>Bi-specific antibodies (bs-Abs) represents a significant leap forward in the field of antibody engineering. As this field continues to advance rapidly and offers a range of molecular designs, production methods, and clinical uses, it is essential to summarize the platforms and technologies that enable the development of bsAbs. The review provides a brief overview, types and functions, current therapeutic uses, limitations and future prospects of bs-Abs with a brief outlook of research needs in this new field of therapeutics.</p> Recent Findings <p>Bi-specific antibodies (bsAbs) engineering design has evolved from initial scFv-based constructs to over 30 commercial platforms. These platforms encompass IgG-like formats such as knobs-into-holes, DEKK, and ART-Ig, along with non-IgG-like formats like BiTE, DART, and tandem. Clinical improvements have also occurred, with the FDA approving Blinatumomab for B-cell acute lymphoblastic leukemia (B-ALL) and Amivantamab for non-small cell lung cancer. Currently, more than 35 additional candidates are in clinical trials for both solid and hematological cancers. Despite promising outcomes, challenges such as immunogenicity, manufacturing complexity, and target specificity limitations remain, underscoring the need for improved bsAb designs and development strategies.</p> Summary <p>BsAbs constitute an expanding group of next-generation therapies with greater clinical impact. Continued refinement of engineering platforms, coupled with advances in discovery technologies and manufacturing, is accelerating their translation and supporting development of more precise and adaptable therapeutic options.</p>